LDA/MDA achieved in 60% of PsA pts on (mostly) bDMARDs. Combo baseline features: TJC>3, SJC>5, CRP>10 mg/l, HAQ>0.5, enthesitis, dactylitis, BMI>30  & sDMARDs tx constitutes negative predictive impact on MDA/LDA after 1 yr. #EULAR2022 POS0080 @RheumNow https://t.co/PugwiuSMPm https://t.co/nqadEjA3Xe

Izokibep - potent and small molecule IL-17A inhibitor Phase 2 study in PsA patients Fast onset, met ACR50 primary endpoint AE included site reaction and candida infection @RheumNow #EULAR2022 ABST#OP0258 https://t.co/vZ4xmnhyhl

I could listen to Dennis McGonagle talk about enthesitis all day. If you missed it, one to check out later #EULAR2022 @RheumNow https://t.co/8pRKqMB06j

Add on MTX does not impair UST immunogenicity in PsA. #EULAR2022 POS0079 @RheumNow https://t.co/CalEn7KpsX https://t.co/NZUqdX0XKo

52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores. Synovial hypertrophy most responsive. Hands and feet, wrist and knees most affected and responsive. @RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa

#POS0757 #EULAR2022 What is the perception of #lupus patients on #COVID19 recovery? A survey of 202 pts from BILAG-BR (N=20 case+, 3 hospitalised) reported full recovery from covid in only 1/3 of patients. These pts would need extra support @RheumNow https://t.co/SdH223Lfoa

Novel composite DAPSA LDA +IGA < or = to 1 may be a reliable predictor in long-term PsA skin/joint response (and easier to get than PASDAS in clinic.) @AlexisOgdie #EULAR2022 POS0082 @RheumNow https://t.co/dmMjGcsIcm https://t.co/BHRlGenCyl

Style guide: welcome to the modern era of #EULAR2022 (and here I am, stuck-in-the-mud still wearing my collared shirt/blue blazer) @RheumNow https://t.co/MXXHWF7Q47

More from GLORIA. Tapering pred 5mg after 2 years. Some minor increase in disease activity (DAS28 0.26) with no evidence of adrenal insufficiency. Can successfully withdraw long term steroids! @RheumNow #EULAR2022 OP0270 https://t.co/IV9iJLY22v https://t.co/ZXdwxlXorK

Merola et al. BE COMPLETE trial of bimekizumab (dual 17A/17Fi) in TNF-IR PsA. Week 16 ACR50: 43.4% BKZ vs 6.8% PBO. Rapid response with separation from week 4. @RheumNow #EULAR2022 OP0255 https://t.co/ZaxAeePP6L https://t.co/D5mDdkno3c

Behrens et al. Izokibep (small molecular size IL17Ai, suggested to abrogate issues with tissue distribution of monoclonal abs) in PsA. ACR50 52% in 80mg, 48% in 40mg, 13% in PBO. @RheumNow #EULAR2022 https://t.co/FUS50ax79C https://t.co/e1n1RbNw1b

Michielsens et al T2T tapering of TNFi in AxSpA and PsA. 72% tapered, 28% discontinued TNFi. Month 12 LDA 69% vs 73%.Month 12 dose 53% vs 91%. Flares 85% vs 78%. Needed more NSAID 54% vs 24% and steroid 30% vs 17%. @RheumNow #EULAR2022 OP0261 https://t.co/EDBPOgg4sX https://t.co/ckPqaTdm4B